Literature DB >> 21678021

Coexistence of multiple endocrine neoplasia type 1 and type 2 in a large Italian family.

Sandra Mastroianno1, Massimo Torlontano, Alfredo Scillitani, Leonardo D'Aloiso, Antonella Verrienti, Nazario Bonfitto, Antonio De Bonis, Leonardo D'Agruma, Lucia Anna Muscarella, Vito Guarnieri, Franca Dicembrino, Marianna Maranghi, Cosimo Durante, Sebastiano Filetti.   

Abstract

To describe the coexistence of mutations of both the multiple endocrine neoplasia type 1 (MEN1) and type 2 (MEN2) genes in a large Italian family and evaluate if it could be associated with more aggressive clinical manifestations of the two syndromes. Blood samples were obtained for genetic and biochemical analyses. The RET gene exons (8, 10, 11, 13, 14, 15, 16, 18) and the MEN1 coding regions, including the exon-intron boundaries, were amplified by PCR and directly sequenced. We identified two germline mutations in the proband: the first one, K666M, located at the exon 11 of RET proto-oncogene and the second one, IVS4+1G>T, located in the MEN1 gene. The functional characterization of IVS4+1G>T variation, located in the splicing donor site of exon 4 of MEN1 gene, caused the in-frame junction of exon 3 to exon 5, thus obtaining a shorter protein. The same proband's germline mutations were found in 16 relatives out of 21 screened subjects: 8 carried IVS4+1G>T, 4 RET K666M, and 4 both the mutations. This is the second report in literature of coexistence in the same family of germline mutations of both RET proto-oncogene and MEN1 gene. The simultaneous presence of the two mutations was not apparently associated with more aggressive diseases, since at last follow-up all patients appeared to be disease-free or well compensated by medical therapy; finally, no one exhibited metastatic diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21678021     DOI: 10.1007/s12020-011-9501-2

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  17 in total

1.  Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases.

Authors:  Syed A Ahmed; Karen Snow-Bailey; W Edward Highsmith; Weimin Sun; Raymond G Fenwick; Rong Mao
Journal:  J Mol Diagn       Date:  2005-05       Impact factor: 5.568

2.  Four novel RET germline variants in exons 8 and 11 display an oncogenic potential in vitro.

Authors:  Marina Muzza; Daniela Cordella; Johny Bombled; Brigitte Bressac-de Paillerets; Fabiana Guizzardi; Zelia Francis; Paolo Beck-Peccoz; Martin Schlumberger; Luca Persani; Laura Fugazzola
Journal:  Eur J Endocrinol       Date:  2010-01-26       Impact factor: 6.664

3.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

Review 4.  Multiple endocrine neoplasia type 1.

Authors:  A A Pannett; R V Thakker
Journal:  Endocr Relat Cancer       Date:  1999-12       Impact factor: 5.678

Review 5.  Guidelines for diagnosis and therapy of MEN type 1 and type 2.

Authors:  M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

Review 6.  Multiple endocrine neoplasia syndrome: genetic basis for clinical management.

Authors:  Tobias Carling
Journal:  Curr Opin Oncol       Date:  2005-01       Impact factor: 3.645

7.  Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma.

Authors:  Leonardo D'Aloiso; Francesca Carlomagno; Michele Bisceglia; Suresh Anaganti; Elisabetta Ferretti; Antonella Verrienti; Franco Arturi; Daniela Scarpelli; Diego Russo; Massimo Santoro; Sebastiano Filetti
Journal:  J Clin Endocrinol Metab       Date:  2005-12-29       Impact factor: 5.958

8.  Coincidence of multiple endocrine neoplasia types 1 and 2: mutations in the RET protooncogene and MEN1 tumor suppressor gene in a family presenting with recurrent primary hyperparathyroidism.

Authors:  Karin Frank-Raue; Susanne Rondot; Wolfgang Hoeppner; Peter Goretzki; Friedhelm Raue; Wieland Meng
Journal:  J Clin Endocrinol Metab       Date:  2005-05-03       Impact factor: 5.958

9.  A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization.

Authors:  Maria D Castellone; Antonella Verrienti; Deva Magendra Rao; Marialuisa Sponziello; Dora Fabbro; Magesh Muthu; Cosimo Durante; Marianna Maranghi; Giuseppe Damante; Stefano Pizzolitto; Giuseppe Costante; Diego Russo; Massimo Santoro; Sebastiano Filetti
Journal:  Clin Endocrinol (Oxf)       Date:  2010-10       Impact factor: 3.478

Review 10.  Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene.

Authors:  Manuel C Lemos; Rajesh V Thakker
Journal:  Hum Mutat       Date:  2008-01       Impact factor: 4.878

View more
  7 in total

1.  Practical evaluation of late-night salivary cortisol: a real-life approach.

Authors:  Shirin Hasani-Ranjbar; Mahsa M Amoli
Journal:  Endocrine       Date:  2012-08       Impact factor: 3.633

2.  A patient with MEN1 typical features and MEN2-like features.

Authors:  Diala El-Maouche; James Welch; Sunita K Agarwal; Lee S Weinstein; William F Simonds; Stephen J Marx
Journal:  Int J Endocr Oncol       Date:  2016-04-08

3.  Medullary Thyroid Carcinoma Associated with Germline RETK666N Mutation.

Authors:  Jian Yu Xu; Elizabeth G Grubbs; Steven G Waguespack; Camilo Jimenez; Robert F Gagel; Julie A Sosa; Rena V Sellin; Ramona Dadu; Mimi I Hu; Chardria S Trotter; Michelle Jackson; Thereasa A Rich; Samuel M Hyde; Steven I Sherman; Gilbert J Cote
Journal:  Thyroid       Date:  2016-10-18       Impact factor: 6.568

Review 4.  Metachronous appearance of second malignancies in medullary thyroid carcinoma (MTC) patients: a diagnostic challenge and brief review of the literature.

Authors:  Maria Alevizaki; Elena Kyratzoglou; Aristoteles Bamias; Marinella Tzanela; Meletios A Dimopoulos; Katerina Saltiki
Journal:  Endocrine       Date:  2013-04-23       Impact factor: 3.633

5.  Novel association of MEN1 gene mutations with parathyroid carcinoma.

Authors:  Luigia Cinque; Angelo Sparaneo; Filomena Cetani; Michelina Coco; Celeste Clemente; Massimiliano Chetta; Teresa Balsamo; Claudia Battista; Eliana Sanpaolo; Elena Pardi; Leonardo D'Agruma; Claudio Marcocci; Evaristo Maiello; Geoffrey N Hendy; David E C Cole; Alfredo Scillitani; Vito Guarnieri
Journal:  Oncol Lett       Date:  2017-05-12       Impact factor: 2.967

Review 6.  Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma.

Authors:  Cosimo Durante; Alessandra Paciaroni; Katia Plasmati; Fabiana Trulli; Sebastiano Filetti
Journal:  Endocrine       Date:  2013-04-14       Impact factor: 3.633

7.  Features of Multiple Endocrine Neoplasia Type 1 and 2A in a Patient with Both RET and MEN1 Germline Mutations.

Authors:  Spandana J Brown; Daniel L Riconda; Feibi Zheng; Gilchrist L Jackson; Liye Suo; Richard J Robbins
Journal:  J Endocr Soc       Date:  2020-02-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.